Skip to main content
VANI
NASDAQ Industrial Applications And Services

Vivani Medical Secures $3.9M in Combined Offering, Director Gregg Williams Participates

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$1.43
Mkt Cap
$100.674M
52W Low
$0.905
52W High
$1.92
Market data snapshot near publication time

summarizeSummary

Vivani Medical finalized a registered direct offering and concurrent private placement, raising $3.9 million, with Director Gregg Williams purchasing a substantial stake.


check_boxKey Events

  • Public Offering Finalized

    Vivani Medical is offering 1,689,200 shares of common stock at $1.48 per share in a registered direct offering, generating approximately $2.0 million in net proceeds.

  • Director Participates in Concurrent Private Placement

    Director and 10% owner Gregg Williams agreed to purchase 1,351,351 shares of common stock at $1.48 per share in a concurrent private placement, contributing approximately $1.9 million in net proceeds. This follows a reported significant purchase on January 20, 2026.

  • Total Capital Raised

    The combined offerings are expected to yield approximately $3.9 million in net proceeds for the company.

  • Use of Proceeds and Runway

    Proceeds will fund research and clinical development of pipeline candidates, working capital, capital expenditures, and general corporate purposes, extending the company's cash runway into mid-2027.


auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of a registered direct offering and a concurrent private placement, raising approximately $3.9 million in net proceeds. The offering, priced at $1.48 per share, includes a substantial purchase of 1,351,351 shares by Director and 10% owner Gregg Williams in a concurrent private placement. This insider participation, following a previously reported significant purchase on January 20, 2026, signals strong confidence from a key stakeholder. While the offering is dilutive for new investors, the capital infusion is crucial for Vivani Medical, a clinical-stage biopharmaceutical company, extending its operational runway into mid-2027 and funding ongoing research and clinical development.

At the time of this filing, VANI was trading at $1.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $100.7M. The 52-week trading range was $0.91 to $1.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed VANI - Latest Insights

VANI
Apr 16, 2026, 6:30 AM EDT
Filing Type: 4
Importance Score:
9
VANI
Mar 26, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
8
VANI
Mar 26, 2026, 4:35 PM EDT
Source: Wiseek News
Importance Score:
8
VANI
Mar 26, 2026, 4:32 PM EDT
Filing Type: 10-K
Importance Score:
7
VANI
Mar 26, 2026, 4:16 PM EDT
Source: GlobeNewswire
Importance Score:
9
VANI
Mar 16, 2026, 6:15 AM EDT
Filing Type: 4
Importance Score:
9
VANI
Jan 28, 2026, 10:01 AM EST
Filing Type: 4
Importance Score:
9
VANI
Jan 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
9
VANI
Jan 27, 2026, 6:01 AM EST
Filing Type: 424B5
Importance Score:
7
VANI
Jan 20, 2026, 9:00 AM EST
Filing Type: 4
Importance Score:
8